NEWARK, Del., Sept. 25, 2026 — According to Future Market Insights, the global diabetic renal nutrition market is projected to grow from USD 333.9 million in 2026 to USD 694.6 million by 2036, expanding at a 7.6% CAGR during the forecast period. The market was valued at USD 310.3 million in 2025.
Demand is being supported by the increasing need for nutrition products that address both glycemic management and renal dietary restrictions. In March 2026, the CDC estimated that 14% of U.S. adults had chronic kidney disease (CKD) and that four in ten adults with diabetes also had CKD, highlighting the expanding patient population requiring coordinated nutritional management.
👉 Get Detailed Market Forecasts, Competitive Benchmarking, and Pricing Trends:
https://www.futuremarketinsights.com/reports/sample/rep-gb-35460
Global Segment Leaders
- Product Type – Diabetes-Renal Dual-Adapted ONS: 48.3% share in 2026. These products combine renal nutrient adaptation with glycemic-management requirements within a single supervised nutrition format.
- CKD Stage – Stage 3: 51.5% share in 2026. Stage 3 represents a substantial patient group requiring structured dietary intervention before dialysis.
- Product Form – RTD: 38.4% share in 2026. Ready-to-drink products offer measured servings without preparation, supporting consistent use across hospitals, dialysis centers, and homecare.
- End User – Homecare: 43.0% share in 2026. Diabetic CKD is a long-term condition, making continued nutrition management outside acute-care settings an important demand channel.
- Sales Channel – Hospital Pharmacy: 48.5% share in 2026. Hospital pharmacies provide a controlled setting where renal dietitians and nutrition teams can evaluate patient requirements before recommending specialized products.
Country-Level Performance
| Country | CAGR | Key Growth Driver |
| South Korea | 7.9% | Specialist nephrology pathways are supporting disease-specific nutrition use as diabetic kidney disease progresses toward kidney failure. |
| USA | 7.3% | CDC estimated in March 2026 that four in ten U.S. adults with diabetes also had CKD, expanding the potential patient pool for structured nutrition management. |
| UK | 7.0% | NHS renal pathways and specialist dietitians support individualized dietary management, while NICE retained individualized dietary management in its CKD guidance reviewed in August 2025. |
| Germany | 6.6% | Statutory reimbursement requirements and the G-BA’s July 2025 evaluation of balanced enteral diets keep clinical purpose and economic appropriateness central to access decisions. |
| Japan | 5.7% | Established nephrology and long-term dietary management place greater emphasis on sustained use, palatability, compact portions, and stage-specific nutrient design. |
The country analysis is based on FMI’s profiled markets for the 2026–2036 forecast period.
Regional Context
South Korea records the highest CAGR among the five profiled countries at 7.9%, reflecting the role of specialist nephrology pathways in managing diabetic kidney disease. The USA follows at 7.3%, supported by a sizeable population living with both diabetes and CKD. The UK is projected to grow at 7.0%, while Germany reaches 6.6% amid a more tightly governed reimbursement environment for medically necessary enteral nutrition.
Japan records a 5.7% CAGR and represents a more mature care environment in which adherence, practical product use, and stage-specific nutritional requirements remain important considerations. The full report covers North America, Latin America, Western Europe, Eastern Europe, East Asia, South Asia and Pacific, and the Middle East and Africa, with analysis covering the five profiled countries and more than 25 additional countries.
👉 Access the Complete Report in PDF Format:
https://www.futuremarketinsights.com/reports/brochure/rep-gb-35460
Drivers, Restraints and Opportunities
Earlier identification of diabetic CKD is expanding the pool of patients entering structured nutrition management before dialysis. This creates demand for formulas that can simultaneously address glucose control and renal nutrient restrictions.
The market also faces a key product-design restraint. Protein, carbohydrate, potassium, phosphorus, sodium, and fluid requirements can change according to CKD stage, laboratory values, and dialysis status. A formula suitable at one stage may not remain appropriate as the patient’s condition progresses.
An opportunity exists in low-volume RTD and modular products that can help extend clinically initiated nutrition into homecare. Products that are easier to carry, consume, reorder, and integrate into daily routines can support continued use following discharge from hospital care.
Competitive Landscape
The diabetic renal nutrition market includes Abbott, Nestlé Health Science, Fresenius Kabi, Danone Nutricia, Victus, Medtrition, Global Health Products, and B. Braun.
Abbott participates through diabetes and renal nutrition brands including Glucerna and Nepro. Fresenius Kabi combines renal nutrition with oral and tube-feeding products, while Nestlé Health Science and Danone Nutricia operate broader medical nutrition portfolios. B. Braun maintains an institutional enteral-care presence, while Medtrition and Global Health Products provide targeted and modular nutrition products.
Recent developments include:
- March 2026: Fresenius Kabi launched Fresubin Plant-Based Tube Feed in the UK as a ready-to-use 1.5 kcal/ml complete tube feed, expanding its institutional enteral nutrition platform.
- October 2025: Nestlé Health Science entered a strategic partnership with the UC Davis Innovation Institute for Food & Health, with chronic kidney disease included among the nutrition research areas.
- March 2025: Global Health Products launched LiquaCel HC, a low-volume product providing 250 calories and 20 g of protein per serving, with dialysis nutrition among its supported uses.
Access Full Report: https://www.futuremarketinsights.com/reports/diabetic-renal-nutrition-market
Analyst Perspective
“The strongest products will be the ones that continue to fit as kidney disease progresses. A renal claim or diabetes positioning alone is not enough. Suppliers need formulas that match a clear stage of care, can be prescribed or recommended with confidence, and remain easy for patients to use after they leave the hospital.”
— Anurag Sharma, Principal Consultant, Healthcare, Future Market Insights
About Future Market Insights
Future Market Insights (FMI) is a leading provider of market research and consulting services, offering syndicated and customized research across industries including healthcare, pharmaceuticals, and food & beverage.
About Future Market Insights (FMI)
Future Market Insights (FMI) is a global market intelligence and consulting firm providing comprehensive market research, competitive intelligence, and strategic business insights across industries. The firm delivers detailed forecasts, technology analysis, and data-driven recommendations that support informed decision-making for manufacturers, investors, distributors, and policymakers worldwide.
For Press & Corporate Inquiries
Rahul Singh
AVP – Marketing and Growth Strategy
Future Market Insights, Inc.
+91 8600020075
